» Articles » PMID: 38850110

Impact of and Gene Polymorphisms on Prognosis and Survival of Patients with Oral Squamous Cell Carcinoma

Abstract

Despite significant efforts in developing new diagnostic and therapeutic modalities, oral squamous cell carcinomas (OSCCs) still exhibit a high recurrence rate, a low five-year survival rate, and an increasing prevalence. Toll-like receptors (TLRs), which initiate and perpetuate immune mechanisms upon activation, have been linked to immune surveillance and the antitumor immune response. The aim of this study was to investigate the association between the polymorphisms of the TLR7 rs3853839 and TLR9 rs187084 genes and OSCC risk, clinicopathological features, and survival. Genotyping was assessed by real-time polymerase chain reaction (PCR) in 95 HPV negative OSCC patients and 107 age- and sex-matched healthy controls. Patients with lymph node metastases had higher frequencies of the TLR9 rs187084 CC variant genotype compared to the major TT genotype (P = 0.020) and to T-allele carriers (combined TT + CT genotypes, P = 0.015). A higher prevalence of advanced stage III was observed in patients with the TLR9 rs187084 variant CC genotype compared to TT (P = 0.047) and to T-allele carriers (TT + CT, P = 0.037). Kaplan-Meier analysis revealed a lower overall survival (OS) rate in patients with the TLR9 rs187084 variant CC genotype compared to the TT genotype (P = 0.010, log-rank test) and to T-allele carriers (TT + CT genotypes, P = 0.002), though it was not an independent predictor of OS. Both TLR9 rs187084 and TLR7 rs3853839 polymorphisms were associated with high alcohol consumption (P = 0.027 and P = 0.001, respectively). The investigated genetic variations were not associated with OSCC susceptibility. The variant CC genotype of the TLR9 rs187084 polymorphism might be a marker of poor survival and tumor progression in OSCC.

References
1.
Moura E, Santos I, Freitas P, Silva D, Dos Santos A, Lira Neto A . Polymorphisms in Toll-like receptors genes changes the host's immune response and is associated with cervical cancer. Immunobiology. 2022; 227(2):152187. DOI: 10.1016/j.imbio.2022.152187. View

2.
Sabree S, Voigt A, Blackwell S, Vishwakarma A, Chimenti M, Salem A . Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist. J Immunother Cancer. 2021; 9(6). PMC: 8183212. DOI: 10.1136/jitc-2021-002484. View

3.
Barreiro L, Ben-Ali M, Quach H, Laval G, Patin E, Pickrell J . Evolutionary dynamics of human Toll-like receptors and their different contributions to host defense. PLoS Genet. 2009; 5(7):e1000562. PMC: 2702086. DOI: 10.1371/journal.pgen.1000562. View

4.
Haeggblom L, Nasman A, Ramqvist T, Haglund C, Hagstrom J, Makitie A . TLR5 and TLR7 are differentially expressed in human papillomavirus-positive and negative base of tongue squamous cell carcinoma, and TLR7 may have an independent prognostic influence. Acta Otolaryngol. 2019; 139(2):206-210. DOI: 10.1080/00016489.2018.1552014. View

5.
Zare R, Anvari K, Mohajertehran F, Farshbaf A, Pakfetrat A, Ansari A . Association between Tissue Expression of Toll-Like Receptor and Some Clinicopathological Indices in Oral Squamous Cell Carcinoma. Rep Biochem Mol Biol. 2022; 11(2):200-208. PMC: 9455186. DOI: 10.52547/rbmb.11.2.200. View